The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted Humanigen’s marketing authorisation submission for Lenzilumab in Covid-19 for expedited Covid-related rolling review, with assessment expected to happen more quickly than a standard rolling review. According to Public Health England, despite 86% of the UK being inoculated with the first dose of the vaccine, the current seven-day hospitalisation rate was approximately 2,500, a 45% increase from the previous period.
The Russian Direct Investment Fund, an investor in the Russian Sputnik V vaccine against Covid-19, has announced the positive safety and tolerability data of the jab during a San Marino vaccination campaign in Europe. The countrywide study was conducted among San Marino individuals who received one or two doses of the vaccine between 4 March and 8 April 2021. The study revealed high tolerability for individuals aged 60 years and above, with no hospitalisations or deaths reported.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
A study by Public Health England, which included more than one million people in at-risk groups, showed Covid-19 vaccines such as the Pfizer and AstraZeneca jabs to be highly effective. The study found overall vaccine effectiveness against symptomatic risk groups to be approximately 60% after one dose of either the AstraZeneca or Pfizer-BioNTech, with little variation by age. It also showed vaccine effectiveness to be 81% with AstraZeneca when people in risk groups aged between 16 to 64 years were administered two vaccine doses. Meanwhile, the Pfizer vaccine was 89% effective for people aged 65 years and older and AstraZeneca 80% effective. For the immunosuppressed, vaccine effectiveness was found to be 74% after a second dose, with similar protection to those who did not fall into a risk group.
